From: Should radioiodine now be first line treatment for Graves’ disease?
Author (ref) | Year | Country | Setting | No of patients | Total/CV mortality RR (95%CI) | Cancer mortality RR (95%CI) |
---|---|---|---|---|---|---|
RAI vs Thyroidectomy | ||||||
Hoffman [20] | 1982 | USA | Hospital | 1005 vs 2141 (RAI vs T) | No difference; RR 1.0 (0.9, 1.2) | No difference; RR 1.0 (0.7, 1.3) (a) |
2015, 2018 | Finland | Registry | 1814 vs 4334 (RAI vs T) | Increased; HR 2.1 (1.7, 2.5) (b) | No difference; RR 1.0 (0.9, 1.2) | |
Giesecke [23] | 2017 | Sweden | Registry | 10,250 vs 742 (RAI vs T) | Increased; HR 1.2 (1.0,1.4) | No difference; HR 0.96 (0.73, 1.3) |
RA1 vs ATD | ||||||
Boelaert [7] | 2013 | UK | Hospital | 764 vs 272 (RAI-Grp A vs ATD) (7a) | Reduced; HR 0.7 (0.5, 0.9) | NA |
764 vs 272 (RAI-Grp B vs ATD) (7b) | No difference; HR 0.9 (0.7, 1.3) | NA | ||||
Okosieme [8] | 2019 | UK | Registry | 250 vs 3587 (RAI-Grp A vs ATD) (8a) | Reduced; HR 0·5 (0·3, 0.9) | NA |
182 vs 3587 (RAI-Grp B vs ATD) (8b) | No difference; HR 1·5, (0·9, 2·4) | NA | ||||
Gronich [24] | 2020 | UK | Database | 2829 vs 13,808 (RAI vs ATD) | Reduced; HR 0.83 (0.72, 0.95) | No difference; HR 1.0 (0.8, 1.2) (a) |